BioMarin Pharmaceutical and its top officers were hit with a securities lawsuit on Thursday in California Northern District Court. The suit, filed by Rolnick Kramer Sadighi on behalf of the Alger Capital Appreciation Fund, accuses the defendants of failing to disclose that the data submitted in support of Valrox, a drug intended to treat hemophilia, was insufficient to obtain FDA approval. Counsel have not yet appeared for the defendants. The case is 3:23-cv-00826, Alger Capital Appreciation Fund et al. v. BioMarin Pharmaceutical Inc. et al.
This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
